LifeSemantics Receives Clinical Trial Approval for 'Prostate Cancer Risk Assessment AI Software'

LifeSemantics, an AI-based healthcare company, announced on the 10th that it has received approval for a clinical trial plan related to cancer risk assessment software.

Accordingly, LifeSemantics plans to initiate a multi-center, single-arm, retrospective, superiority verification, and confirmatory clinical trial to validate the clinical efficacy of software medical devices that indicate the risk of prostate cancer occurrence.

Previously, LifeSemantics was recognized for its technological capabilities through the government-led national research projects Dr.Answer 1.0 and Dr.Answer 2.0, overseen by the Ministry of Science and ICT. The company also acquired two related patents for the ‘Prostate Cancer Staging and Recurrence Prediction Software (SW)’.

Based on its accumulated technological expertise, LifeSemantics has developed innovative technologies such as skin cancer image detection and diagnostic assistance, prostate cancer risk assessment, blood pressure analysis and hypertension complication prediction, and hair count analysis.

Recently, LifeSemantics obtained product approval for AI-based blood pressure analysis, skin cancer image detection and diagnostic assistance, and hospital-use software (hair count analysis) medical devices intended for medical professionals. In particular, on the 8th, it received approval for a clinical trial plan to verify the clinical efficacy of software medical devices that analyze the risk of prostate cancer occurrence, signaling its commitment to advancing this field.

A company representative stated, “Through this approval and clinical trial, we expect to further solidify our position in the medical AI solution market.”